Development of novel treatment for rare cancer "Alveolar soft part sarcoma"
| Project/Area Number |
16H07186
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | Juntendo University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2016-08-26 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 胞巣状軟部肉腫 / チロシンキナーゼ / チロシンキナーゼ阻害剤 / 悪性骨軟部腫瘍 / 希少がん / 分子標的治療 |
|---|
| Outline of Final Research Achievements |
The aim of this study is developing a novel treatment for alveolar soft part sarcoma, which is a rare malignant tumor. We identified multiple tyrosine kinases, which are related to the mechanism of tumor development. We pre-clinically examined anti-tumor effect against alveolar soft part sarcoma by using tyrosine kinase inhibitor. As a result, Cabozantinib and Dasatinib showed significant anti-tumor activity both in vitro and in vivo. These results indicate that identified tyrosine kinases in this study are promising therapeutic target and these tyrosine kinase inhibitors can be a potent new therapeutic option.
|
Report
(3 results)
Research Products
(2 results)
-
[Journal Article] Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma2017
Author(s)
Mukaihara K, Tanabe Y, Kubota D, Akaike K, Hayashi T, Mogushi K, Hosoya M, Sato S,Kobayashi E, Okubo T, Kohsaka S, Saito T, Kaneko K, Suehara Y.
-
Journal Title
PLoS One
Volume: 12(9)
Issue: 9
Pages: 0185321-0185321
DOI
Related Report
Peer Reviewed / Open Access
-
